Physician profile
Pradeep Thapar
NPI 1891889812
$75,568.68
in general payments reported to CMS, 2019-2025
38 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,627 · 2020: $3,425 · 2021: $9,505 · 2022: $9,579 · 2023: $20K · 2024: $14K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $8,170 · Travel and Lodging: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,125.00 |
| Food and Beverage | $8,170.42 |
| Travel and Lodging | $136.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48,588.53 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $7,830.56 | 2020-2025 | Caplyta |
| Allergan, INC. | $4,932.00 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $2,866.82 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $1,323.39 | 2019-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,150.13 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,149.97 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Alkermes, INC. | $871.85 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $758.07 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $670.46 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $627.28 | 2021-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $602.20 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $518.14 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $465.85 | 2022-2025 | Auvelity |
| Tris Pharma INC | $445.51 | 2019-2025 | Dyanavel Xr |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $397.91 | 2019-2025 | Perseris, Sublocade |
| E.R. Squibb & Sons, L.L.C. | $208.03 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $195.36 | 2019-2024 | Jornay Pm |
| Shire North American Group INC | $182.50 | 2019 | |
| Almatica Pharma LLC | $181.96 | 2021-2025 | Loreev Xr |
| Bausch Health US, LLC | $175.92 | 2019-2024 | Wellbutrin, Aplenzin |
| Noven Therapeutics, LLC | $168.40 | 2021-2025 | Xelstrym |
| Orexo US, INC. | $149.48 | 2019-2023 | Zubsolv |
| Idorsia Pharmaceuticals US INC | $148.73 | 2022-2024 | Quviviq |
| Eisai INC. | $146.14 | 2020-2025 | |
| Neos Therapeutics, LP | $117.80 | 2019 | |
| Jazz Pharmaceuticals INC. | $107.22 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.74 | 2019 | |
| Arbor Pharmaceuticals, INC. | $98.65 | 2019-2020 | |
| Biogen, INC. | $73.74 | 2025 | Skyclarys, Zurzuvae |
| Braeburn INC. | $66.45 | 2024-2025 | Brixadi |
| Adlon Therapeutics L.P. | $57.10 | 2019-2020 | |
| Uswm, LLC | $51.27 | 2022-2023 | Lucemyra, Zimhi |
| Vertical Pharmaceuticals, LLC | $50.67 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $33.15 | 2019-2021 | |
| Luye Pharma (USA) LTD. | $19.51 | 2025 | Erzofri Extended-Release |
| Sun Pharmaceutical Industries INC. | $19.23 | 2019 | |
| Livanova USA, INC. | $18.96 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Thapar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.